Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
While most immuno-oncology drugs target specific cellular pathways, Dive Biosciences targets the acidic tumor microenvironment itself. This is framed as a foundational "upstream checkpoint" that degrades the entire immune "ecology," suppressing every type of immune cell in the tumor's vicinity at once, rather than one receptor at a time.
Related Insights
Most cell therapies target a single antigen on cancer cells. Luminary engineers its cells to recognize three different receptors. The therapy only needs one of the three to be present to work, making it significantly harder for cancer cells to mutate and "escape" the treatment.
Early 4-1BB agonists failed due to severe liver toxicity. Excalipoint's bispecifics solve this by requiring one arm to bind to a tumor before the other activates T-cells. This localizes the immune response, preventing systemic toxicity and reviving a previously failed mechanism for cancer therapy.
The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.
The company's buffering agent is naturally drawn to the most acidic areas of the body. Since tumors actively export acid, they create a "magnet" for the therapy. This approach leverages basic chemical kinetics for targeting, bypassing the need for complex biological receptors and acting as an upstream solution.
For decades, tumor acidity was considered a mere consequence of metabolic activity (the Warburg effect). The modern understanding underpinning Dive’s strategy is that this acidity is a causal factor that actively drives tumor invasion, treatment resistance, and immune suppression, making it a viable therapeutic target.
T-cells have natural inhibitory signals, or "brakes" (like PD-1), to prevent over-activation. Some cancers exploit this. Checkpoint inhibitor drugs block these brakes, unleashing a patient's existing T-cells to attack cancer cells more aggressively. This approach has been miraculous for cancers like melanoma.
By delivering a high, sustained local drug concentration, Nenology's platform shifts cancer cell death from a passive process (apoptosis) to immunogenic cell death. This releases antigens that actively prime the immune system, creating a secondary anti-tumor effect and potentially boosting the efficacy of other immunotherapies.
Instead of focusing solely on T-cells, Create's platform first targets myeloid cells, which constitute up to 60% of some solid tumors. Programming these cells transforms the tumor microenvironment, enabling a 5-10x influx of CD8 T-cells. This overcomes a key barrier for T-cell therapies in solid tumors.
Successful immunotherapies like anti-PD-1 work by shifting the battlefield's arithmetic. They enhance the efficiency of each T-cell, allowing one cell to destroy five or ten cancer cells instead of three. This turns the fight into a 'numbers game' that the immune system can finally win.
The company's drug formulation doesn't rely on specific cell receptors, which cancers often mutate to evade treatment. Instead, it uses a physical diffusion process to permeate any cancer cell, rendering receptor-based mutations irrelevant and overcoming a major hurdle in cancer therapy.
